Temps réel estimé Cboe Europe  -  17/05 13:54:46
221.50 SEK   +2.03%
10/05Le suédois Orphan Biovitrum AB (publ) élit Bo Jesper Hansen comme nouveau membre du conseil d'administration
28/04Swedish Orphan Biovitrum AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2022
28/04Le fabricant de médicaments suédois Sobi confirme ses perspectives de revenus pour l'exercice 22 après la croissance du premier trimestre.
ETFs positionnés sur SWEDISH ORPHAN BIOVITRUM AB (PUBL)ETFs et Trackers avec Trackinsight
ETF PoidsVar. 5joursRatingGéographie
IShares STOXX Europe Small 200 (DE) - EUR0.65%4.84%Europe
IShares OMX Stockholm Capped - SEK0.63%5.35%Suède
IShares STOXX Europe 600 Health Care (DE)...0.26%1.84%Europe
Lyxor Net Zero 2050 S&P Europe Climate PAB...0.06%3.65%-Europe
Xtrackers S&P Europe ex UK 1D - EUR0.06%3.00%-Europe
Vanguard FTSE Developed Europe ex UK Accu...0.05%3.78%-Europe
Vanguard FTSE Developed Europe ex UK - EUR0.05%3.06%Europe
Franklin FTSE Europe ex U.K. Index ETF - D...0.05%0.45%-Europe
Lyxor 1 Stoxx Europe 600 ESG (DR) - EUR0.05%3.86%-NC
Amundi Prime Europe DR (C) - EUR0.05%3.85%-Europe
AMUNDI PRIME EUROPE - - EUR0.05%3.87%-Europe
L&G Europe Equity (Responsible Exclusions)...0.05%4.18%-Europe
Lyxor Core STOXX Europe 600 (DR) - Monthl...0.04%0.00%Europe
Lyxor Core STOXX Europe 600 (DR) - Acc - EUR0.04%4.16%Europe
IShares STOXX Europe 600 (DE) - EUR0.04%3.95%Europe
Franklin FTSE Europe Hedged ETF - USD0.04%4.30%Europe
Franklin FTSE Europe ETF - USD0.04%3.13%Europe
Vanguard FTSE Developed Europe EUR Accumu...0.04%3.99%-Europe
Vanguard FTSE Developed Europe - EUR0.04%4.11%Europe
Franklin STOXX Europe 600 Paris Aligned Cl...0.02%3.83%-Europe

Copyright © 2009 Morningstar. All Rights Reserved. The information, data and opinions expressed (“Information”) and contained herein: (1) are proprietary to Morningstar and/or its content providers and are not intended to represent investment advice or recommendation to buy or sell any security; (2) may not be copied or distributed without express license to do so; and (3) are not warranted to be accurate, complete or timely. Morningstar reserve its rights to charge for access to these Ratings and/or Rating report. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this Rating, Rating Report or Information contained therein.
Durée : Période :
Swedish Orphan Biovitrum AB (publ) : Graphique analyse technique Swedish Orphan Biovitrum AB (publ) | Zone bourse
Graphique plein écran
Evolution du Compte de Résultat
Recommandation moyenne ACHETER
Nombre d'Analystes 8
Dernier Cours de Clôture 217,10 SEK
Objectif de cours Moyen 245,88 SEK
Ecart / Objectif Moyen 13,3%
Révisions de BNA
Secteur et Concurrence